Heterocyclic ligands for integrin imaging and therapy
US8486370B2 · kind B2 · utility
6Cited by
1References
49Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 7, 2007 |
| Grant date | Jul 16, 2013 |
| Priority date | — |
| Expiry date | Feb 6, 2029 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides α4β1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unnatural amino acid or a D-amino acid, and wherein n is an integer of from 3 to 20. Methods are provided for administering the ligands for treating cancer, inflammatory diseases, and autoimmune diseases. Also provided are methods for administering the ligands for imaging a tumor, organ, or tissue in a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.